bbio: the cashflow

MyFinsight

For the quarter ending 2025-09-30.

Cash Flow Overview

No enough data to generate the overview

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net loss	-538,303	-
Stock-based compensation	98,385	-
Loss on extinguishments of debt	-21,155	-
Noncash interest expense on deferred royalty obligations	86,460	-
Amortization of debt discount and issuance costs	4,515	-
Depreciation and amortization	3,999	-
Noncash lease expense	3,443	-
Net loss from equity method investments	-51,579	-
Change in fair value of the embedded derivative associated with the deferred royalty obligation	11,062	-
Noncash income from an equity method investment	7,769	-
Gain on deconsolidation of subsidiaries	0	-
Gain from investment in equity securities, net	0	-
Other noncash adjustments, net	1,217	-
Accounts receivable, net	111,796	-
Inventories	23,356	-
Prepaid expenses and other current assets	17,527	-
Other assets	-568	-
Accounts payable	9,084	-
Accrued compensation and benefits	3,212	-
Accrued research and development liabilities	347	-
Operating lease liabilities	-4,757	-
Deferred revenue	-9,480	-
Other liabilities	53,030	-
Net cash used in operating activities	-389,490	-
Purchases of marketable securities	10,876	-
Maturities of marketable securities	8,000	-
Purchases of investments in equity securities	0	-
Proceeds from sales of investments in equity securities	0	-
Proceeds from special cash dividends received from an investment in equity securities	2,302	-
Payment for intangible assets	8,495	-
Purchases of property and equipment	1,064	-
Decrease in cash and cash equivalents resulting from deconsolidation of subsidiaries	0	-
Net cash provided by (used in) investing activities	-10,133	-
Proceeds from issuance of 2031 notes-A2031Convertible Senior Notes	575,000	-
Issuance costs and discounts associated with 2031 notes/ issuance costs and discounts associated with term loan under amended financing agreement-A2031Convertible Senior Notes	12,034	-
Repurchase of common stock	48,276	-
Proceeds from a royalty obligation under the royalty purchase agreement	300,000	-
Issuance costs associated with a royalty obligation under the royalty purchase agreement	3,010	-
Proceeds from term loan under the amended financing agreement-Financing Agreement	0	-
Issuance costs and discounts associated with 2031 notes/ issuance costs and discounts associated with term loan under amended financing agreement-Financing Agreement	0	-
Repayment of term loans	459,000	-
Repayments of deferred royalty obligations	6,896	-
Proceeds from issuance of common stock through public offerings, net	0	-
Proceeds from common stock issuances under espp	6,414	-
Proceeds from stock option exercises, net of repurchases	14,523	-
Transactions with noncontrolling interests	1,550	-
Repurchase of rsu shares to satisfy tax withholding	6,796	-
Restricted cash, noncurrent	-	1,698
Net cash provided by financing activities	361,475	-
Restricted cash, current	-	449
Net increase (decrease) in cash, cash equivalents and restricted cash	-38,148	-
Cash and cash equivalents, at carrying value, ending balance	-	748,953
Cash and cash equivalents at beginning of period	683,244	-
Cash, cash equivalents, restricted cash, and restricted cash equivalents	-	751,100
Cash and cash equivalents at end of period	645,096	-

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Time Plot

Show the time plot by selecting a row from the table.

bbio: the cashflow